Healthcare Industry News: Bladder Cancer
News Release - May 26, 2010
Predictive Biosciences Expands Leadership Team and Commercial Sales ForceSupports Growth Strategy and Anticipated Launch of Novel Bladder Cancer Test
LEXINGTON, Mass. & CLEVELAND--(HSMN NewsFeed)--Predictive Biosciences, a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty provider of anatomic pathology products and services nationwide, today announced the expansion of the Company’s leadership team with the appointment of two vice presidents: James R. Groves as vice president of lab operations and Mark J. Smith as vice president of information technology. The Company has also actively expanded its sales force to support growth within its existing commercial portfolio as well as the anticipated market launch of Predictive’s novel, non-invasive Bladder Cancer assay.
As vice president of lab operations, Mr. Groves brings over 20 years of experience in clinical laboratory operations and will be a key player in driving and supporting the strategic plans and growth of OncoDiagnostic Laboratory (ODL), Predictive’s Cleveland-based commercial division. Prior to joining Predictive, Mr. Groves was the head of operations for SED Medical Laboratories, where he provided technical support and leadership for the organization’s medical facilities. He also served as chief operating officer and vice president of clinical operations at the Beijing International Heart Hospital, where he designed and implemented patient-focused training programs.
Mr. Smith brings over 28 years of information technology (IT) and software expertise that will be critical in refining and leading the Company’s IT strategy as vice president of information technology. He most recently served as vice president of information technology at Athena Diagnostics where, for the past 16 years, he was responsible for the Company’s IT strategy and the development of customer-interfacing systems. Previously, Mr. Smith held the position of manager of information systems for Whistler Corporation, where he managed the integration, development and maintenance of corporate computer systems.
“We are very pleased to welcome Jim and Mark to the Predictive Biosciences team,” stated Peter Klemm, Ph.D., president and chief executive officer. “Their combined experience in diagnostics and healthcare will greatly enhance the infrastructure of our IT and lab operations, and is well-aligned with the strategic direction of the Company. The expansion of our sales force also marks a critical step as we prepare to launch our first non-invasive diagnostic assay for Bladder Cancer.”
Predictive’s urinary biomarker based assay for Bladder Cancer is the first in its unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence, allowing certain groups of patients to be excluded from undergoing invasive procedures such as cystoscopy.
About Predictive Biosciences
Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the Company is building a unique portfolio of assays for cancer management, first targeted at the growing Bladder Cancer and prostate cancer survivor populations. Predictive Biosciences’ commercial division, OncoDiagnostic Laboratory (ODL), is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists and other subspecialty physicians. For additional information, please visit www.predictivebiosci.com
Source: Predictive Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.